Precision NeuroMed is thrilled to share some exciting news: Dr. Jeff Sherman, MD, FACP, is joining our  Scientific Advisory Board! Dr. Sherman’s appointment marks a significant milestone for PNM as we continue to advance our mission.

Dr. Sherman joins an exceptional group of advisors, including Dr. Susan Chang, Dr. Mitchel Berger, and Dr. Raj Puri, each of whom brings a wealth of insight to our team. With more than 25 years of experience in the pharmaceutical industry, Dr. Sherman is widely recognized for his leadership in regulatory and clinical strategy, as well as his commitment to therapeutic development for rare and underserved conditions.

Dr. Sherman served as Chief Medical Officer (CMO) at Horizon Therapeutics, where he played a pivotal role in guiding the company’s clinical programs and regulatory initiatives. His tenure culminated in Horizon’s acquisition by Amgen, underscoring the impact of his contributions. Additionally, Dr. Sherman was CMO and Executive Vice President at NeoPharm, Inc., where he gained extensive knowledge of IL13-PE38 and the landmark PRECISE Study—expertise that will be invaluable as we advance our own lead asset.

At PNM, Dr. Sherman will provide strategic guidance on the remanufacturing, regulatory clearance, and eventual commercialization of our flagship therapy. His proven track record, combined with his passion for improving patient outcomes, will be instrumental as we navigate the complex landscape of drug development and bring new hope to patients and families. We are honored to welcome Dr. Sherman to our team and look forward to the many ways his expertise will help shape the future of Precision NeuroMed.